您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > NSC 405020
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
NSC 405020
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
NSC 405020图片
CAS NO:7497-07-6
规格:≥98%
包装与价格:
包装价格(元)
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议
1g电议

产品介绍
NSC 405020 (NSC405020; NSC-405020) is a novel small molecule inhibitor of MT1-MMP (Membrane type-1 matrix metalloproteinase) that targets the noncatalytic domain of MMP with potential antineoplastic activity. It inhibits MMP by directly interacting with PEX domain of MT1-MMP and affecting PEX homodimerization but has not catalytic activity of MT1-MMP. It specifically targets PEX domain rather than the catalytic domain of MT1-MMP with IC50 >100 μM and does not inhibit the catalytic activity of MT1-MMP or MMP-2. NSC 405020 significantly inhibits tumor growth in vivo.
理化性质和储存条件
Molecular Weight (MW)260.16
FormulaC12H15Cl2NO
CAS No.7497-07-6
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 52 mg/mL (199.9 mM)
Water: <1 mg/mL
Ethanol: 52 mg/mL (199.9 mM)
Solubility (In vivo)1% DMSO+30% polyethylene glycol+1% Tween 80: 5 mg/mL
SynonymsNSC 405020; NSC405020; NSC-405020;

Chemical Name: 3,4-Dichloro-N-(1-methylbutyl)benzamide

InChi Key: ARDYECYBETXQFD-UHFFFAOYSA-N

InChi Code: InChI=1S/C12H15Cl2NO/c1-3-4-8(2)15-12(16)9-5-6-10(13)11(14)7-9/h5-8H,3-4H2,1-2H3,(H,15,16)

SMILES Code: O=C(NC(C)CCC)C1=CC=C(Cl)C(Cl)=C1

实验参考方法
In Vitro

In vitro activity: NSC 405020 is a noncatalytic inhibitor of MT1-MMP, directly interacts with PEX domain of MT1-MMP. NSC 405020 affects PEX homodimerization but not catalytic activity of MT1-MMP. NSC 405020 (100μM) inhibits migration of cells with high level of MT1-MMP, with a reduction of migration efficiency by about 75%. NSC 405020 does not inhibit migration of cells with low level of MT1-MMP and does not inhibit cell adhesion on collagen.


Kinase Assay: Assays are conducted in wells of a 24-well, 8 μm pore size Transwell plate. A 6.5-mm insert membrane is coated with 0.1 mL COL-I (300 μg/mL in MEGM) and then air dried for 16 hours. The collagen coating is rehydrated for 1 hour in 0.2 mL MEGM. The inner chamber contains MEGM-10% FBS as a chemoattractant. The compounds (10–100 μmol/L) or DMSO (0.1%–1%) are added to both inner and outer chambers. Before plating in the outer chamber, cells (5×104) are coincubated for 20 minutes with the compounds or DMSO in MEGM. Cells are allowed to migrate for 16 to 18 hours. The cells remaining on the top surface of the membrane are removed with a cotton swab. The cells on the bottom surface of the membrane are fixed and stained (0.2% crystal violet). The incorporated dye is extracted with 1% SDS and the A570 is measured.


Cell Assay: Assays are conducted in wells of a 96-well flat bottom, white wall plates. 184B5-MT and MCF7-β3/MT cells (5×104) are grown for 16 hours in MEGM-10% FBS and DMEM-10% FBS, respectively. 184B5-MT cells are replenished with fresh MEGM (0.1 mL per well) and incubated for an additional 24 hours in the presence of the compounds (100 μM) or vehicle (1% DMSO). MCF7-β3/MT cells are replenished with fresh DMEM-10% FBS (0.1 mL per well) and incubated for an additional 6 hours in the presence of the compounds (400 μM) or vehicle (2% DMSO). The viable cells are counted using a luminescent ATP-Lite assay.

In VivoNSC 405020 (0.5 mg/kg, intratumoral injection) significantly represses tumor growth. NSC 405020 causes a fibrotic, ΔPEX-like tumor phenotype and increases the level of COL-I.
Animal modelBALB/c nu/nu mice injected with MCF7-β3/WT and MCF7-β3/ΔPEX cells
Formulation & DosageDissolved in 2% DMSO; 0.5 mg/kg; Intratumoral injection
References

Cancer Res. 2012 May 1;72(9):2339-49.